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Abstract 
Background: Biologics are usually licensed according to the “one dose fits all” principle. It is therefore 
suspected that a significant number of psoriasis patients are overtreated. However, evidence for successful 
dose reduction of biologics in psoriasis is scarce. The aim of this study was to investigate whether the dosing 
interval of three biologics, adalimumab, etanercept, or ustekinumab could be prolonged successfully in 
patients with plaque psoriasis. 
 
Methods 
In a prospective exploratory cohort study, 59 psoriasis patients on maintenance treatment with adalimumab, 
etanercept, or ustekinumab were included. After a run-in period of six weeks, the dosing interval of the 
biologics was prolonged according to a predefined schedule. Our primary objective was to determine the 
proportion of patients that could maintain a successful prolongation of the per label dosing interval. 
Secondary objectives were to evaluate the predictive value of baseline serum trough concentrations for 
successful dosing interval prolongation and to explore the feasibility of dosing interval prolongations in off-
label treated patients. 
 
Results 
In the per label group, 7 out of 16 (44%) adalimumab patients, 5 out of 16 (31%) etanercept patients, 2 out of 
10 (20%) ustekinumab patients achieved a successful dosing interval prolongation. Baseline serum trough 
concentrations did not differ significantly between patients with successful dosing interval prolongation and 
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failures. In the off-label group, prolongation in patients with already extended intervals was unsuccessful. For 
patients with shortened intervals, minor prolongation was successful in 3 out of 17 (17.6%) patients. 
 
Conclusion 
Prolongation of the per label biologic dosing interval was feasible in approximately 30% of psoriasis patients 
with stable minimal disease activity and can reduce costs in clinical practice. Baseline serum trough 
concentrations were not predictive for successful dosing interval prolongation. 
Keywords: biologics, adalimumab, etanercept, ustekinumab, dosing interval prolongation, psoriasis 
 
Background 
Biologics are effective drugs for the treatment of moderate to severe plaque psoriasis. As a result, their use is 
increasing and many new biologics and biosimilars are being developed. Biologics are usually licensed and 
marketed according to the “one dose fits all” principle, and dose regimens with fixed dosing intervals are 
recommended. However, a number of studies in patients with stable rheumatoid arthritis (RA) have shown 
that the per label biologic dose can be reduced without a subsequent increase in disease activity (1-3). 
Recently, biologic dose reduction and dosing interval prolongation have also been described in patients with 
psoriasis (4, 5). 
Measurement of high trough concentrations supports these dose reductions in RA, since adalimumab 
levels above 8 µg/mL in RA patients were found to have no clear additional beneficial effect on disease 
activity (6). Similar findings were reported in psoriasis where one-third (44 out of 135) of psoriasis patients 
had adalimumab concentrations above 7 µg/mL without further increase in clinical improvement (7). Chen et 
al. also showed that after 24 weeks of adalimumab dose reduction with 50%, the trough concentrations above 
the cutoff value of 6.4 µg/mL predicted persistent remission in patients with RA (3). The adalimumab trough 
concentrations were significantly higher in RA patients with persistent remission (median 10.5 µg/mL) or 
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with low disease activity (4.5 µg/mL) than in those with disease flare (0.9 µg/mL). These data suggest that a 
substantial proportion of patients on biologics are indeed overtreated. In view of these studies in RA and 
psoriasis, we hypothesized that biologic trough concentrations could be a useful indicator for dose 
reduction of adalimumab and possibly other biologics that are currently being used for patients with 
psoriasis. 
Adalimumab phase III studies have shown that complete discontinuation of biologic treatment in patients 
with psoriasis who are in remission is not recommendable. Papp et al. showed that after the 
discontinuation of adalimumab treatment, 69% (178/256) of psoriasis patients showed a relapse after a 
median of five months (8). Similarly, Ortonne et al. demonstrated a time to relapse of only two months in 
240/359 psoriasis patients in whom etanercept was discontinued (9). Complete discontinuation in 
ustekinumab-treated patients was also unsuccessful, 60% of patients had  recurrence of disease activity 
after the median time of 15 weeks (10). Therefore, tapering of biologics appears to be a better option than 
complete discontinuation.  
In Europe, off-label dosing of biologics is quite common in daily clinical practice (5, 11). This usually means 
not only dose escalation (e.g., doubling the dose), but also dose reductions, primarily by dosing interval 
prolongation. In daily practice, intensified dosing regimens are often applied in the early treatment phase and 
then continued as maintenance treatment, even when patients have been in remission for quite some time (12-
14). Disadvantages of unnecessary or excessive long-term dosing are not only the potentially higher risk of 
treatment-related side effects, such as serious infections and development of malignancies, but also the high 
costs that are associated with the use of biologic drugs (15, 16). In Europe, pharmaceutical companies have 
negotiated prices as high as 15,000 Euro per patient annually (17). As a result of the large numbers of patients 
now being treated with biologics, the pharmaceutical costs are a substantial proportion of the total health care 
budget. At present, evidence of successful prolongation of the per label dosing interval of biologics in 
psoriasis is scarce. Therefore, our primary objective was to determine the proportion of patients that could 
maintain a successful prolongation of the per label dosing interval. Secondary objectives were to evaluate the 
predictive value of baseline trough concentrations for successful dosing interval prolongation. In addition, we 
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explored the feasibility of dosing interval prolongations in off-label-treated patients that were treated with 
either shorter of longer intervals according to the treatment label. 
 
Methods 
Study design 
This was a prospective exploratory cohort study conducted at the department of Dermatology in the 
Erasmus Medical Center, Rotterdam, The Netherlands, between June 2013 and March 2016. The study 
was approved by the Institutional Review Board of the Erasmus University Medical Center Rotterdam 
(MEC-2013-050). The study was conducted according to the guidelines of Good Clinical Practice. The 
trial is registered in the European Clinical Trials Database (EudraCT) under EudraCT number 2012-
005809-53. 
 
Patients and treatments 
All included patients were 18 years or older and received maintenance treatment with adalimumab, 
etanercept, or ustekinumab for at least six months. In order to be eligible for the study, patients were 
required to have an absolute Psoriasis Activity and Severity Index (PASI) score below 8. Patients who 
used other anti-psoriatic co-medication such as methotrexate, fumarates, or acitretin were excluded; 
pregnant or lactating women were also excluded. All patients provided written informed consent before 
any of the study procedures were executed. Patients were recruited from the dermatology outpatient 
clinic of our hospital. 
“Per label use” was defined as the use of the biologic for the approved indication, in the approved 
dosage and route of administration. In our study, “off-label use” implies that the dose or dose interval of 
either of the three biologics used in this study was not according to the package insert approved by our 
national drug regulatory agency. 
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Study procedures 
All patients were on maintenance treatment with adalimumab, etanercept, or ustekinumab with a dose 
and dosing interval prescribed by their dermatologist. Patient visits were scheduled at weeks 0, 6, 18, 30, 
42, 54, 66, and 78. At each study visit, data were collected on biologic trough concentration and PASI 
scores, adverse events, and laboratory testing (full blood count, aspartate aminotransferase, alanine 
aminotransferase, bilirubin, gamma-GT, serum creatinine, sedimentation rate, C-reactive protein, and 
urine analysis). The drug adherence was self-monitored, and empty syringes were collected during the 
outpatient visits. To determine whether a patient had stable disease activity, a run-in period of six weeks 
was used before the start of the study where the PASI score of the patient was not allowed to fluctuate 
more than three points. In all patients, the dosing interval of the biologic was prolonged every 12 weeks 
during a 42-week period (see supplementary table 1 for predefined schedule). In case of an unacceptable 
increase in disease activity judged by the patient or a rise of the PASI score above 8, the last effective 
treatment regimen was resumed and was maintained during the remainder of the study period. Patients 
were followed up to week 78. 
Patients in whom the dosing interval could be prolonged according to the protocol without loss of self-
reported efficacy or deterioration of the PASI score above 8 were designated “successful.” Patients in whom 
the dosing interval could not be prolonged according to our protocol were designated “failure. ”Failure” also 
included patients who objected to continuing with the dosing interval prolongation because of (self and 
investigator reported) exacerbation of their psoriasis or for other (personal) reasons. In the majority of 
patients, tapering consisted of dosing interval extensions (supplementary table 1 
http://links.lww.com/TDM/A189) and in only a minority as dose reductions (with unchanged interval). In 
this paper, tapering will only be referred to as dosing interval prolongations. AC
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Psoriasis Activity and Severity Index (PASI) and Physician Global Assessment (PGA) 
 
The Psoriasis Activity and Severity Index (PASI) is a validated tool for monitoring the disease activity. 
The PASI is calculated based on the intensity of redness, thickness, scaling, and the affected surface area 
of the skin (18). The PASI score is the main outcome measure for success of treatment in clinical practice 
and clinical trials. The 5-point PGA scale is a modified and more simplified tool for evaluating plaque 
psoriasis severity and improvement in clinical trials. It is divided in clear, almost clear, mild, moderate, 
and severe score for the disease activity (19). 
 
Dermatology Life Quality Index (DLQI) 
It is a 10-item questionnaire used to measure the impact of a skin disease on the quality of life of an affected 
person. Each question refers to the impact of the skin disease on the patient’s life over the previous week. The 
DLQI can provide more insight into the impairment of quality of life of psoriasis patients and can support 
more appropriate clinical decisions. 
 
Biologic assay 
Anti-TNFa biologic (adalimumab and etanercept) concentration was determined by an ELISA-based 
assay of Sanquin (Sanquin Reagents, Sanquin, Amsterdam, The Netherlands), according to 
manufacturer’s instructions. Briefly, ELISA plates pre-coated with TNFa-specific murine monoclonal 
antibody (CLB-TNF5, Sanquin) were incubated with recombinant TNFa, followed by biologic containing 
calibrators, controls, and samples, diluted in HPE (High Performance ELISA) buffer (Sanquin). Binding 
of anti-TNFa biologic was detected with a horse-radish peroxidase-labeled monoclonal antibody specific 
for the adalimumab or etanercept idiotype. Both assays were in-house validated by Sanquin (Diagnostic 
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Services, Biologics Lab). The adalimumab assay is a CE-IVD kit of Sanquin Reagents B.V. 
(http://www.sanquin.nl/repository/reagentia/ifu/M2910_2_level-adalimumab_en.pdf), whereas the 
etanercept assay is a research assay and has no CE-IVD label. The adalimumab assay had 99% accuracy 
at 2 µg/mL and etanercept had 94% accuracy at 1 µg/mL of a spiked human serum sample. The lower 
limit of detection was 0.06 and 0.15 µg/mL for adalimumab and etanercept, respectively. The lower limit 
of quantification was 0.06 and 0.18 µg/mL for adalimumab and etanercept, respectively; the calibrator 
range was 0–25 and 0–289 ng/mL for adalimumab and etanercept, respectively.  The manual is available 
at http://www.sanquin.nl/en/products-services/reagents/product-categories/biologicals/. Day-to-day 
imprecision of these assays was 10.0% and 5.6%, performed in 20 days for adalimumab concentration, 
and was 11.3% and 8.1%, performed in 19 days for etanercept concentration, based on repetitive testing 
of low and high controls. For ustekinumab measurements, an analogous ELISA-based assay was used; 
however, this time, it was executed by Sanquin (Diagnostic Services, Biologicals Lab). In this in-house 
validated assay, plates were pre-coated with one of the ustekinumab targets, interleukin-12, to capture 
ustekinumab, and, for detection, rabbit polyclonal antibody specific for ustekinumab idiotype was used 
for detection (20). For ustekinumab PK measurements prior to Feb 2017, we gathered the following data: 
accuracy was 97% at 0.4 µg/mL of spiked human serum sample; lower limit of detection was 0.02 ng/mL; 
lower limit of quantification was 0.02 µg/mL; and the calibrator range was 0.0004–0.025 µg/mL. The 
reportable range was 0.02–16 µg/mL. Day-to-day imprecision of the ustekinumab assay was 9%, based 
on three days of repetitive testing of a single (medium) control.  
Measurement of anti-drug antibody against a biologic (ADA) was only performed in patients with 
undetectable biologic trough levels, as it is more likely to find ADA in absence of detectable drug (21). 
ADA was also determined by Sanquin (Diagnostic Services, Biologicals Lab), using in-house-validated 
ELISA-based assays. Etanercept has no clinically relevant immunogenity, and therefore measurement of 
ADA was not indicated (22). 
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Statistical analysis 
For numeric variables that were not normally distributed according to the Shapiro-Wilk test, we used the 
Mann Whitney U-test to compare groups. For the analysis of the associations between categorical data, 
we used Pearson’s Chi Square test or Fisher’s exact test, as appropriate. The difference between the 
biologic baseline trough concentration of the successes and the failures was analyzed with the Mann 
Whitney U-test. Statistical significance was defined as a two-tailed p value of 0.05 or less. For statistical 
data analysis, SPSS statistics software (version 23.0., IBM,  Armonk, NY) was used. 
 
Results 
 
Patients 
This study started in June 2013, and the last patient completed the follow-up in March 2016. In total, 64 
patients were enrolled, and after the run-in period of six weeks, 59 patients were included (Fig. 1). 
Patient demographics and baseline disease characteristics are presented in Table 1. The BMI, PASI, 
PGA, and DLQI were significantly higher in the ustekinumab group compared with the adalimumab and 
etanercept group. 
Seventeen out of 20 patients on adalimumab therapy (85%) completed the 78-week study, 18 of 21 
patients (86%) in the etanercept therapy group completed the study, and 17 of 18 patients (94%) in the 
ustekinumab therapy completed the study. Seven patients did not complete the study because of 
withdrawal of consent (n = 3) or because they were lost to follow up (n = 4) because of migration 
(moved to a different city or country). In each biologic group, patients had different maintenance dosing 
intervals, but the main cohort started with the per label dose and dosing interval (Fig. 1). The per label 
dosing interval for adalimumab was 40 mg once every two weeks, for etanercept 50 mg every week, and 
for ustekinumab 45 mg (<100 kg) or 90 mg (>100 kg) every 12 weeks. For etanercept and adalimumab, 
the dose was unchanged during the study protocol, only the dose interval was prolonged step by step. In 
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ustekinumab-treated patients, the dose was also unchanged, except in three patients, in whom the dose 
was reduced from 90 to 45 mg. 
 
Prolongation of the dosing interval 
Per label dosing  
At week 78, in the adalimumab group (40 mg every two weeks), seven out of 16 (44%) patients had achieved 
a successful dosing interval prolongation. Six of these seven patients had a successful interval prolongation of 
100% (40 mg every four weeks) and one of 50% (40 mg every three weeks). In the etanercept group (50 mg 
every week), 5 out of 16 (31%) patients had a successful dosing interval prolongation of 100% (50 mg every 
two weeks). 
In the ustekinumab group (45 mg every 12 weeks), two out of nine (22%) patients had a successful dosing 
interval prolongation of 100% (45 mg every 24 weeks). 
 
Off-label dosing 
The dosing interval could not be extended for the patients who were already being treated with adalimumab 
40 mg every three weeks at baseline (n = 4). In all four patients, the severity of psoriasis increased after 
dosing interval prolongation, and patients requested to be treated with their original regimen of adalimumab 
40 mg every three weeks. 
In the escalated dose group, etanercept 50 mg twice a week, one out of five (20%) patients had a successful 
interval prolongation of 100% (50 mg once a week; per label dosing interval). 
In the escalated dose group (ustekinumab 45 mg every eight weeks), one out of three (33%) patients was  
successfully prolonged to 45 mg every 14 weeks. There was only one patient on ustekinumab 45 mg every 10 
weeks. In this patient, the dosing interval was successfully prolonged to 45 mg every 12 weeks ((Fig. 1). In 
the other off-label treated patients dosing interval prolongations were unsuccessful. 
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Trough concentrations 
The median baseline trough concentration of adalimumab in patients in whom the dosing interval was 
successfully prolonged was higher compared to the concentrations in the failures, although the difference was 
not statistically different (8.8 µg/mL, 95% CI [5.2; 10.6] vs. 5.3 µg/mL, 95% CI [4,5; 10,9] p = 0.37) (Fig. 
3A). The median baseline trough concentration of etanercept did not differ significantly between the 
successful prolongations vs. failures (4.1 µg/mL, 95% CI [0.0; 4.7] vs. 3.6 µg/mL, 95% CI [1.3; 6.9], p = 1.0) 
(Fig. 3b). Also, the median baseline trough concentration of ustekinumab did not differ significantly between 
the successful prolongations vs. failures (0.6 µg/mL, 95%CI [0.3;0.9] vs. 0.2 µg/mL, 95% CI [0,2; 0,5] p = 
0,33) (Fig. 3c). 
 
Undetectable trough concentrations and the presence of ADA 
In the adalimumab group, three patients had, on two occasions, undetectable concentrations. In one of these 
patients, the presence of ADA was detected once; for this patient, psoriasis was in remission. In the 
etanercept group, two patients had, each on two occasions, undetectable concentrations and four patients 
showed an undetectable concentration at a single occasion. In total, 9 patients had 14 occasions in which 
undetectable trough concentrations were found. In the ustekinumab group, all patients had detectable trough 
concentrations, and the measurement of ADA was therefore not indicated. 
 
Loss of efficacy 
In the majority (n = 55) of patients, the PASI score remained below 8. In one patient in the per label 
adalimumab group and in two ustekinumab-treated patients on off-label escalated dose, the prolongation of 
the dosing interval caused an increase in disease activity that led to a PASI above 8. In one patient on off-
label escalated etanercept dose, the PASI increased above 8 before any interval prolongation, and in these 
cases, a dose prolongation was not performed. All of the four patients mentioned in this paragraph reached 
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remission after they were retreated according to their original dosing regimen. 
 
Occurrence of adverse events (AE) 
The most frequent minor adverse events were respiratory and urinary tract infections. In the per label 
adalimumab group, three severe adverse events (SAE) occurred. One patient developed meningitis, and his 
psoriasis exacerbated. His PASI score reached 7.6, and at the end of the study, he was switched from 
adalimumab to ustekinumab. The other two patients suffered from rhabdomyolysis and had a coronary artery 
stent placement, respectively. In the per label ustekinumab group, two SAEs occurred (cerebrovascular 
accident and miscarriage). In the off-label group, one patient on ustekinumab was admitted to the hospital 
with myocardial infarction. All patients recovered without sequelae. 
Discussion 
The main finding of this study is that in approximately 30% of psoriasis patients on maintenance treatment 
with adalimumab, etanercept, or ustekinumab, the per label dosing interval could be prolonged without loss 
of clinical response. 
The adalimumab group had the highest percentage of patients (44%) in whom the dosing interval could be 
prolonged successfully. Baniandres et al. also showed that the adalimumab dose could be successfully 
reduced in 57.7% of patients in a cross-sectional study among 112 psoriasis patients (5). Rodrigo-Nicolas 
et al. showed 75% successful adalimumab dosing interval prolongations in 12 patients (4). Their follow-up 
time of 46.5 weeks was shorter than our follow-up time of 78 weeks. In our study, 50% (three out of six) of 
the failures occurred after a follow-up of 52 weeks, potentially explaining the higher success rate of Rodrigo-
Nicolas et al. 
In the ustekinumab per label group, a low rate (22%) of successful interval prolongation was achieved. The 
ustekinumab-treated patients had a significantly higher PASI and DLQI score at baseline and they had 
previously been treated with significantly more biologics before they started using ustekinumab. Possibly the 
lower success rate in the ustekinumab group was related to more treatment-resistant disease. 
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Trough concentrations of etanercept and ustekinumab at baseline did not correlate with the success of 
subsequent dosing interval prolongations. Concentration–effect relationships have not been shown for these 
two biologics. Neither Mahil et al. nor Menting et al. found a correlation between etanercept or ustekinumab 
trough concentrations and clinical response in newly treated psoriasis patients (20, 23, 24). Van Herwaarden 
et al. also showed that adalimumab and etanercept trough concentrations were not predictive for successful 
dose reductions (24). In the adalimumab group of our study cohort, there was a trend toward higher trough 
concentrations in the patients in whom dosing interval could be prolonged, although the difference was not 
statistically significant. Our results support the finding of Menting et al. who showed that adalimumab 
concentrations above 7 µg/mL do not provide additional clinical efficacy (7). The majority (71%) of 
adalimumab-treated patients in whom the dosing interval could be prolonged had an adalimumab trough 
concentration above 7 µg/mL at baseline. 
Another important secondary aim of our study was the safety of dosing interval prolongations. Reported risk 
of biologic dose reductions such as irreversible loss of efficacy and immunogenicity (25) appeared to be 
low/absent in this study. Dose reductions have a major influence on the costs of treatment, if patients can be 
treated with considerably less injections per year because the dosing interval is doubled. Potentially, this can 
result in treatment cost savings of 7,021 euros per adalimumab-treated patient; 6,939 euros per etanercept-
treated patient; and 7,130 euros per ustekinumab-treated patient per year. Indirect costs should also be taken 
into account for a formal and more accurate cost-effective evaluation.; However, this was beyond the scope 
of our study. Some studies in rheumatoid arthritis patients on treatment with biologics have published 
promising data on major savings in the costs for biologics after dose reduction (26, 27). 
In clinical practice, patients are often treated off-label; therefore, we also included these patients in our study. 
Successful prolongations were less often observed in the off-label group. In the off-label adalimumab and 
ustekinumab group that was already on a prolonged dosing interval, further dosing interval prolongation was 
unsuccessful. 
A limitation of this exploratory study was the relatively small number of patients per biologic. A control 
group of patients who continued maintenance treatment without dose interval prolongation was not a part 
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of the current study design. For larger prospective trials, inclusion of a control group will help to estimate 
the incidence of psoriasis flares, in patients treated with unchanged dose and dose interval. Moreover, we 
chose a relatively high PASI of 8 as a cutoff for inclusion in this study and to define the maximum allowed 
deterioration in disease activity upon dosing interval prolongation. In retrospect, a PASI of 5 would have 
been more appropriate since this has recently been suggested as a cutoff for intervention (28). However, the 
higher PASI cutoff does not appear to have influenced our results in this light, since all included patients had 
low disease activity with the highest PASI at baseline of 4.8 (etanercept group). Furthermore, most of the 
patients that experienced deterioration of their psoriasis upon dosing interval prolongation chose to return to 
their previous dosing interval before a PASI of 5 was reached. Also, none of the patients that were designated 
as “successful” upon dosing interval prolongations had a PASI above 5. Despite these limitations, this is one 
the first observational biologic tapering studies reflecting a real-life setting in a clinical dermatology practice. 
A definition of clinical criteria to select patients in whom dose interval prolongation can be applied would be 
helpful. Intuitively one would think that a longer duration of remission, no failed biologic treatments prior to 
the current treatment, a very low PASI score, and higher biologic concentrations would increase the chance 
of successful dose interval prolongation. Larger cohorts of patients are needed to evaluate the predictive value 
of the mentioned clinical criteria. 
In conclusion, safe and robust prolongation of biologic dosing intervals was achieved in almost 30% of 
patients. This can reduce the treatment costs without clinically relevant loss of efficacy. Larger (cost-
effectiveness) studies are warranted to corroborate our findings and to investigate whether adalimumab 
baseline trough levels can indeed predict the successful interval prolongation in psoriasis patients with 
already stable mild disease. Moreover, these investigations could possibly be extended to the newly 
introduced anti-IL17 biologics for which the data on safe dosing interval prolongations in psoriasis are also 
lacking. 
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Figure legends 
Fig. 1: Study flow chart showing patients who are included in the study per biologic and dosing interval 
groups. The number of patients with successful prolongation of the dosing interval and failures is 
depicted. Patients who did not complete the study are also shown for each group. 
Fig. 2a: Comparison of adalimumab trough concentrations at baseline after the run-in period of six weeks 
in patients with a successful dosing interval prolongation and the failures. The concentrations at baseline 
of each patient are represented by a circle (○). The horizontal line in the graph represents the median. 
Fig. 2b: Comparison of etanercept trough concentrations at baseline after the run-in period of six weeks in 
patients with a successful dosing interval prolongation and failures. The concentrations at baseline of each 
patient are represented by a circle (○). The horizontal line in the graph represents the median. 
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Fig. 2c: Comparison of ustekinumab trough concentrations at baseline after the run-in period of six weeks 
in patients with a successful dosing interval prolongation and failures. The concentrations at baseline of 
each patient are represented by a circle (○). The horizontal line in the graph represents the median. 
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Table 1 Baseline patient characteristics. 
 
 
Patient 
characteristics 
Adalimumab (n= 20) 
  n (%) 
Etanercept (n= 21) 
  n (%) 
Ustekinumab (n= 18) 
 n (%) 
Gender, n (%) 
Males 
Females 
 
16 (80) 
  4 (20) 
 
12 (57) 
  9 (43) 
 
11 (61) 
  7 (39) 
Race, n (%) 
Caucasian  
Black  
Asian 
Other 
 
13 (65) 
  1 (  5) 
  5 (25) 
  1 (  5) 
 
15 (71) 
 
  4 (19) 
  2 (10) 
 
14 (78) 
 
  2 (11) 
  2 (11) 
Age (years), mean 
(SD) 
43.2 (13.2) 50.6 (14.4) 52.0 (15.3) 
Body mass index 
(kg/m2), median 
(Q1, Q3) 
 
24 (23, 29) 
 
26 (23, 29) 
 
28 (26, 31) 
PASI score,  
Median (Q1, Q3) 
 
 
1.7 (0.3, 3.2)  
 
3.2 (1.3, 4.8) 
 
2.9 (1.8, 3.9) 
PGA score 
Clear 
Almost clear 
Mild 
 
 
  6 (30) 
14 (70) 
 
  4 (19) 
15 (71) 
  2 (10) 
 
  3 (17) 
13 (72) 
  2 (11) 
DLQI score,  
Median (Q1, Q3) 
 
0.0 (0.0 , 2.5) 
 
1.0 (0.0 , 5.0) 
 
1.5 (0.0 , 5.3) 
Duration of 
psoriasis, years,  
Median (Q1, Q3) 
 
 
15 (8 , 28) 
  
 
20 (14, 34) 
 
 
22 (14, 39) 
History of psoriatic 
arthritis, n (%) 
  5 (25)   2 (10)   2 (11) 
Biologic-naïve 
before start current 
biologic , n (%) 
12 (60) 15 (71)   4 (22) 
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Figure 1 
 
 
 
 
                                                                 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 40mg/2wk (n=16) 
• Successes (n=7) 
From 40mg/2wk to: 
40mg/4wk (n=6) 
40mg/3wk (n=1) 
• Failures (n=6) 
• Lost to follow up (n=3) 
Dose at last visit: 
       40mg/3wk (n=2) 
       40mg/2wk (n=1) 
Included in study (n=64) 
40mg/3wk (n=4) 
 
• Failures (n=4) 
 
50mg/1wk (n=16) 
• Successes (n=5) 
 
From 50mg/1wk to: 
50mg/2wk (n=5) 
 
• Failures (n=9) 
• Lost to follow up 
(n=1)Dose at last vin=1) 
 
• Withdrew consent (n=1) 
45mg/12wk (n=9) 
• Successes (n=2) 
From 45mg/12wk to: 
45mg/24wk 
 
• Failures (n=7)  
Per label 90mg/12wk (n=1) 
• Failures (n=1) 
 
 
50mg 2x wk (n=5) 
• Successes (n=1) 
From 50mg 2x wk to: 
50mg/1wk 
• Failures (n=3) 
• Withdrew consent (n=1) 
45mg/8wk (n=3) 
• Successes (n=1) 
From 45mg/8wk to 
45mg/14wk  
• Failures (n=2) 
45mg/10wk (n=1) 
• Successes (n=1) 
From 45mg/10wk to 
45mg/12wk  
45mg/16wk (n=1) 
• Withdrew consent (n=1) 
90mg/8wk (n=2) 
• Failures (n=2) 
90mg/16wk (n=1) 
• Failures (n=1) 
Not eligible after run-in period (n=2) 
Withdrew consent after run-in period (n=3) 
Patient analyzed in study (n=59) 
 Adalimumab (n=20)                            Etanercept (n=21)                                Ustekinumab (n=18) 
Per label treated 
Off label treated 
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Figure 2A 
 
Figure 2B 
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Figure 2C 
 
* Some circles (○) are on the same place in the graph because some patients have the same 
concentrations at baseline. 
** The six patients who failed to complete the study were not included. 
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